Stock Groups

French health authority advises against Moderna COVID-19 vaccine for under 30s -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO A healthcare worker makes a syringe containing the Moderna COVID-19 Vaccine during the COVID-19 pandemic that hit Manhattan, New York City. This was done at a SOMOS Community Care pop-up vaccination center. It took place on January 29, 2021. REUTERS/Mike

PARIS (Reuters – France’s public health agency has suggested that people below 30 years old be given a vaccine Pfizer (NYSE:) Comirnaty COVID-19 vaccination when it is available in place of Moderna (NASDAQ) Inc’s Spikevax jab – which had comparatively greater risks of heart-related complications

Although it does not hold the legal authority to ban drugs or license them, the Haute Autorite de Sante, which acts as an advisor for the French health system, has cited the “very rare” risk of Myocarditis. This is a serious heart condition that was highlighted in data from the Moderna vaccine, and in the French study released Monday.

HAS published its opinion on Monday, stating that “within the population under 30 this risk seems to be about five times less with Pfizer’s Comirnaty Jab than Moderna’s Spikevaxjab.”

HAS indicated that HAS’ recommendation which applies regardless of whether the vaccine is used as a second, third, or fourth “booster” dose would still be valid, until further scientific research on the subject becomes available.

The Moderna vaccine is recommended for people over 30. It has a slightly higher effectiveness.

Last month, the European Union’s drug regulator approved Moderna’s booster vaccine. It stated in its review that it may be administered to anyone aged 18 or older, and at least six months following the last dose.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts, buy/sell signal, and quotes. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]